Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn
Sender
S
Department of Surgery/Urology, University of Toronto, Toronto, Ontario, Canada. s.herschorn@utoronto.ca
Stothers
Lynn
L
Carlson
Kevin
K
Egerdie
Blair
B
Gajewski
Jerzy B
JB
Pommerville
Peter
P
Schulz
Jane
J
Radomski
Sidney
S
Drutz
Harold
H
Barkin
Jack
J
Paradiso-Hardy
Fran
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002170:Canada / Q000453:epidemiology; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D011812:Quinuclidines / Q000008:administration & dosage*; D012720:Severity of Illness Index; D000069464:Solifenacin Succinate; D011795:Surveys and Questionnaires; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014987:Xerostomia / Q000139:chemically induced / Q000453:epidemiology
D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; C005419:oxybutynin; D000069464:Solifenacin Succinate